Biologics like monoclonal antibodies are innovative molecules that have in some cases revolutionized modern medicine due to unprecedented efficacy; however, experience shows that this efficacy also expands to unwanted side effects. Several principles of how mAbs can target human autoimmune diseases are known, ranging from intervention with pleiotropic cytokine pathways to inhibition of T-cell migration. Direct cyto-toxicity is a classical principle of targeted therapies against tumours. All ofthese mechanisms are inherently associated with certain safety problems; however, regulatory measures can be implemented that nevertheless allow for a relatively safe administration of such drugs to patients. Such regulatory measures include a restriction of the indication to certain patients, usually those suffering from a more severe stage of the disease, and provision of educational information to prescrib-ers and patients. Further research is needed to elucidate the exact mechanisms of action behind the typical safety problems. While most hypotheses appear convincing, still other unknown mechanisms could be responsible, and detailed knowledge could help further reduce the risks for patients.
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.